Emmanuel Moreau, Université Laval

Research

Antimitotiques Cancers Colorectaux Cancers Colorectaux Métastatiques Et Chimiorésistants Chimiothérapie Personnalisée Développement De Médicaments Anticancéreux Modulateurs D'Ahr Promédicaments Antimicrotubules

Latest papers

Mechanism of action of N-phenyl-N'-(2-chloroethyl)ureas in the colchicine-binding site at the interface between alpha- and beta-tubulin.
Bioorganic & medicinal chemistry · 2009
A comparative molecular field and comparative molecular similarity indices analyses (CoMFA and CoMSIA) of N-phenyl-N'-(2-chloroethyl)ureas targeting the colchicine-binding site as anticancer agents.
Bioorganic & medicinal chemistry · 2008
N-Phenyl-N'-(2-chloroethyl)urea analogues of combretastatin A-4: Is the N-phenyl-N'-(2-chloroethyl)urea pharmacophore mimicking the trimethoxy phenyl moiety?
Bioorganic & medicinal chemistry letters · 2007

All 5 publications

Latest funding

Développement translationnel de l'AIMZ-938 comme thérapie de précision pour les cancers colorectaux réfractaires aux traitements
CIHR · 2026 · Principal investigator
$1,262,250

All 1 grants and awards

5 publications.

01

Mechanism of action of N-phenyl-N'-(2-chloroethyl)ureas in the colchicine-binding site at the interface between alpha- and beta-tubulin.

Fortin S, Wei L, Moreau E, Labrie P, Petitclerc E, Kotra LP, C-Gaudreault R

Bioorganic & medicinal chemistry2009

DOI: 10.1016/j.bmc.2009.03.056 PMID: 19398206

02

A comparative molecular field and comparative molecular similarity indices analyses (CoMFA and CoMSIA) of N-phenyl-N'-(2-chloroethyl)ureas targeting the colchicine-binding site as anticancer agents.

Fortin S, Labrie P, Moreau E, Wei L, Kotra LP, C-Gaudreault R

Bioorganic & medicinal chemistry2008

DOI: 10.1016/j.bmc.2007.11.004 PMID: 18023585

03

N-Phenyl-N'-(2-chloroethyl)urea analogues of combretastatin A-4: Is the N-phenyl-N'-(2-chloroethyl)urea pharmacophore mimicking the trimethoxy phenyl moiety?

Fortin S, Moreau E, Lacroix J, Teulade JC, Patenaude A, C-Gaudreault R

Bioorganic & medicinal chemistry letters2007

DOI: 10.1016/j.bmcl.2007.01.023 PMID: 17291753

04

N-Phenyl-N'-(2-chloroethyl)ureas (CEU) as potential antineoplastic agents. Part 2: role of omega-hydroxyl group in the covalent binding to beta-tubulin.

Fortin S, Moreau E, Patenaude A, Desjardins M, Lacroix J, Rousseau JL, C-Gaudreault R

Bioorganic & medicinal chemistry2007

DOI: 10.1016/j.bmc.2006.11.005 PMID: 17118664

05

Optimized N-phenyl-N'-(2-chloroethyl)ureas as potential antineoplastic agents: synthesis and growth inhibition activity.

Moreau E, Fortin S, Desjardins M, Rousseau JL, Petitclerc E, C-Gaudreault R

Bioorganic & medicinal chemistry2005First author

DOI: 10.1016/j.bmc.2005.07.048 PMID: 16165366

Développement translationnel de l'AIMZ-938 comme thérapie de précision pour les cancers colorectaux réfractaires aux traitements

Principal investigatorCIHR2026Project Grant

Principal investigators: Fortin, Sébastien; Benoit-Biancamano, Marie-Odile; C.-Gaudreault, René; Diorio, Caroline; Droit, Arnaud; Durocher, Francine; Moreau, Emmanuel; Simard, Chantale

Keywords: Antimitotiques; Cancers Colorectaux; Cancers Colorectaux Métastatiques Et Chimiorésistants; Chimiothérapie Personnalisée; Développement De Médicaments Anticancéreux; Modulateurs D'Ahr; Promédicaments Antimicrotubules

$1,262,250

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2026

Subject: Prospective PhD student: Antimitotiques Dear Professor Moreau, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Mechanism of action of N-phenyl-N'-(2-chloroethyl)ureas in the colchicine-binding site at the interface between alpha- and beta-tubulin." (2009), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Développement translationnel de l'AIMZ-938 comme thérapie de précision pour les cancers colorectaux réfractaires aux traitements" (2026), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]